How can the United States make insulin more affordable for patients, when there are multiple points at which players in the drug industry raise the price?
This debate is highlighted in a recent news article in Kaiser Health News, discussing attempts to decrease patients' out-of-pocket costs and their potential impact.
To learn more, check out the ADL's March 15, 2023 Highlighted Article:
Why Does Insulin Cost So Much? Big Pharma Isn’t the Only Player Driving Prices
You can find the journal articles cited in this news item here:
Insulin in America: A Right or a Privilege?
Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018